AAPS National Biotechnology Conference 2025: Adapting Flow Imaging Microscopy for Biotherapeutics Analysis
In this recap of a poster presentation, Austin Daniels of Yokogawa Fluid Imaging Technologies explains how flow imaging microscopy can detect the amount and types of both subvisible and visible particles in samples not often detected by traditional methods.
Following the AAPS National Biotechnology Conference 2025 (AAPS Bio), BioPharm International® caught up with Austin Daniels, PhD, an application scientist for Yokogawa Fluid Imaging Technologies, who presented a poster at the event, “Using Flow Imaging Microscopy to Meet Particulate Matter Standards for Biotherapeutics.”
Flow imaging microscopy is effective in this application, according to Daniels, because imaging-based methods have been generally shown to be more sensitive to translucent particles in samples, such as protein aggregates, compared to legacy methods.
“What this results in is, it gives researchers a better sense of the actual particle load in their therapies, and that type of information can be valuable when developing biotherapeutics, because if you have an accurate depiction of the actual particle content in your sample, you can make decisions—whether you're designing the therapy or manufacturing it—to try to keep your particle concentrations low,” Daniels says in the interview. “And by using this more sensitive information as part of your formulation design and product development, you can basically minimize your particle content to make it extremely likely that you'll always meet USP [United States Pharmacopeia] guidelines on both subvisible and visible particles, as well as just controlling for the often-severe safety risks that these particles can pose for patients.”
Click the video above to watch the full interview.
AAPS Bio took place in Boston from May 4–7, 2025.
Click here for all of PharmTech Group’s coverage of AAPS Bio 2025.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
